Small XERF studies reported mostly transient redness, swelling, or discomfort, but they cannot rule out uncommon harms. FDA 510(k) K251327 clears XERF for electrocoagulation and hemostasis, not a specific skin-lifting claim. An FDA recall concerns particular XERF EFFECTOR 60 tip lots. Ask the treating professional about your health history, current device notices, and a plan if your skin reacts.
What did the human studies report?
In the 39-person, four-site study, all participants received two sessions. Investigators reported no persistent adverse events during short-term follow-up; expected redness and swelling were described as mild and transient. The study followed people through 90 days after the final treatment. That is reassuring within its limits, but 39 participants cannot reveal every uncommon problem or the long-term risk profile.
The separate 16-person report also described mild, temporary adverse events. Its patient group was small and selected from routine clinical records. Neither paper is a substitute for the treating professional’s assessment of your medications, implants, skin condition, or prior procedures.
What exactly did the FDA clear?
The FDA indications-for-use document for K251327 states that XERF is intended for dermatologic and general surgical procedures for electrocoagulation and hemostasis. A 510(k) substantial-equivalence decision permits marketing for the listed use; it is not an FDA endorsement of every aesthetic claim on an advertisement. When someone says “FDA approved for skin lifting,” ask them to show the exact indication. The public FDA record is available to everyone.
Does the tip recall affect every XERF treatment?
No such conclusion follows from the recall notice. The FDA record for XERF EFFECTOR 60 identifies specific model and lot information and says the manufacturer initiated corrective action after manufacturing defects could, on rare occasions, lead to adverse events. It does not establish that the participating Garden City location has affected inventory. It is reasonable to ask how a location verifies its tips against current notices and what it does if a lot is affected.
“Is it safe?” invites a slogan. Ask who checks the device and consumable notices, who is present during treatment, what signs mean treatment should stop, and whom you can reach afterward if a reaction develops.
What health details belong in the consultation?
The prospective study excluded people with factors including pregnancy or recent pregnancy, implanted pacemakers or similar electrical devices, relevant metal implants, permanent fillers or facial implants, infected tissue in the treatment area, and recent procedures that could interfere with assessment. These were study exclusions, not a complete universal list of XERF contraindications. Share your own history directly with the treating professional and ask them to use the current device instructions.
The American Academy of Dermatology recommends asking about the treating clinician’s experience, alternatives, risks, recovery, and expected result before any cosmetic procedure. If an answer skips your specific skin or health history, it is incomplete.
Five questions to take with you
- Who will perform and supervise treatment, and how often have they treated skin like mine?
- What history, medicines, devices, or recent treatments would change the plan?
- What temporary reactions are expected, and what would be a reason to call promptly?
- How are current FDA and manufacturer notices checked for the device and tips?
- What alternative would you recommend if XERF is a poor fit?
For a Garden City XERF consultation request, use the existing Detroit Beauty Connect form; do not include medical records. Book a free consultation
Sources and how to read them
We distinguish device descriptions, regulatory records, human clinical reports, and research on radiofrequency as a category. Findings in a small study or another device should not be treated as a prediction for one XERF patient.
- FDA, XERF 510(k) K251327 record
- FDA, XERF indications for use, K251327
- FDA, XERF EFFECTOR 60 recall record
- Weiss et al., prospective XERF study, 2026
- Erlich et al., retrospective XERF study, 2026
- American Academy of Dermatology, cosmetic-treatment questions
Researched by Detroit Beauty Connect, September 27, 2026. Informational only; this page is not a diagnosis, a treatment plan, or a claim of clinician review. Ask the treating professional for advice specific to you.